Sherbrooke Park Advisers LLC Acquires Shares of 4,185 Amedisys, Inc. (NASDAQ:AMED)

Sherbrooke Park Advisers LLC bought a new stake in Amedisys, Inc. (NASDAQ:AMED - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 4,185 shares of the health services provider's stock, valued at approximately $380,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Quantinno Capital Management LP boosted its position in Amedisys by 48.1% during the 4th quarter. Quantinno Capital Management LP now owns 59,911 shares of the health services provider's stock worth $5,439,000 after acquiring an additional 19,454 shares during the last quarter. Nomura Holdings Inc. bought a new stake in shares of Amedisys in the fourth quarter worth $395,000. Occudo Quantitative Strategies LP acquired a new position in Amedisys during the fourth quarter worth $295,000. Moore Capital Management LP bought a new position in Amedisys in the fourth quarter valued at $817,000. Finally, Gotham Asset Management LLC grew its position in Amedisys by 77.4% in the fourth quarter. Gotham Asset Management LLC now owns 246,918 shares of the health services provider's stock valued at $22,418,000 after purchasing an additional 107,720 shares in the last quarter. Institutional investors and hedge funds own 94.36% of the company's stock.

Amedisys Stock Performance

AMED stock traded down $0.02 during trading hours on Friday, reaching $93.55. The stock had a trading volume of 11,450 shares, compared to its average volume of 417,572. The stock has a market capitalization of $3.07 billion, a PE ratio of 37.15, a price-to-earnings-growth ratio of 1.78 and a beta of 0.96. The stock has a 50-day simple moving average of $93.34 and a 200 day simple moving average of $91.63. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19.

Amedisys (NASDAQ:AMED - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.12. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The business had revenue of $594.78 million during the quarter, compared to the consensus estimate of $597.43 million. During the same period last year, the business posted $1.03 EPS. Amedisys's revenue was up 4.1% on a year-over-year basis. Analysts predict that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on AMED shares. Stephens restated an "equal weight" rating and set a $101.00 price objective on shares of Amedisys in a research note on Tuesday, March 4th. Royal Bank of Canada reissued an "outperform" rating and set a $100.00 price target on shares of Amedisys in a research report on Wednesday, April 16th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $100.75.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.